Page last updated: 2024-12-11

6-benzylthioinosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-benzylthioinosine: a subversive substrate of T gondii adenosine kinase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6477178
CHEMBL ID60662
SCHEMBL ID7617372
MeSH IDM0465909

Synonyms (11)

Synonym
purine, 6-benzylthio-9-beta-d-ribofuranosyl-
(2r,3r,4s,5r)-2-(6-benzylsulfanylpurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
6-benzylthioinosine
bdbm50240561
(2r,3r,4s,5r)-2-(6-(benzylthio)-9h-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
(2r,3r,4s,5r)-2-(6-(benzylthio)-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
(2r,3r,4s,5r)-2-(6-benzylsulfanyl-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
CHEMBL60662 ,
(2r,3r,4s,5r)-2-(6-benzylsulfanylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
SCHEMBL7617372
Z1980901773
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Equilibrative nucleoside transporter 1Homo sapiens (human)IC50 (µMol)1.69820.00013.688363.0000AID330912
Equilibrative nucleoside transporter 1Homo sapiens (human)Ki0.03650.00040.10381.1000AID239557; AID392456
Adenosine kinaseToxoplasma gondiiKi26.00008.90008.90008.9000AID343761; AID478199
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine kinaseToxoplasma gondiiKm2.40001.10001.96672.4000AID33981
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
neurotransmitter uptakeEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleobase-containing compound metabolic processEquilibrative nucleoside transporter 1Homo sapiens (human)
xenobiotic metabolic processEquilibrative nucleoside transporter 1Homo sapiens (human)
neurotransmitter transportEquilibrative nucleoside transporter 1Homo sapiens (human)
xenobiotic transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
lactationEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleobase transportEquilibrative nucleoside transporter 1Homo sapiens (human)
adenine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transportEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleoside transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
cytidine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
uridine transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
adenosine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
inosine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
hypoxanthine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
thymine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
excitatory postsynaptic potentialEquilibrative nucleoside transporter 1Homo sapiens (human)
cellular response to glucose stimulusEquilibrative nucleoside transporter 1Homo sapiens (human)
cellular response to hypoxiaEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine-containing compound transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
transport across blood-brain barrierEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
guanine transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
uracil transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine nucleobase transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleobase transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
neurotransmitter transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
adenine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
guanine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
uracil transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleoside transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
cytidine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
uridine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine- and adenosine-specific:sodium symporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
basolateral plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
apical plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
presynapseEquilibrative nucleoside transporter 1Homo sapiens (human)
postsynapseEquilibrative nucleoside transporter 1Homo sapiens (human)
plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID343761Binding affinity to purified Toxoplasma gondii adenosine kinase2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID675314Binding affinity to human synthetic proadrenomedullin N-terminal 20 peptide assessed as reduction in absorbance at 1 uM after 1 hr by monoclonal antibody method2012European journal of medicinal chemistry, Sep, Volume: 55Identification of first proadrenomedullin N-terminal 20 peptide (PAMP) modulator by means of virtual screening and NMR interaction experiments.
AID584546Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID392456Inhibition of human ENT12009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1).
AID584547Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID330912Binding affinity to ENT1 transporter2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.
AID239557Inhibition of [3H]NBTI binding to equilibrative nucleoside transport protein 1 (ENT1) in human erythrocyte membranes2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines.
AID584550Cytotoxicity against mouse J774A1 cells2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID33981Binding affinity at Toxoplasma gondii adenosine kinase.2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID478199Binding affinity to Toxoplasma gondii adenosine kinase after 20 mins by radioactivity method2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (53.33)29.6817
2010's7 (46.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.56 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]